On July 7, 2023, the PhenomeX Inc. (NasdaqGS:CELL) announced that its Board of Directors (Board), with the support of management and legal advisors, has launched a process to explore, review and evaluate a range of potential strategic alternatives focused on addressing capital requirements and maximizing stockholder value. The Board has approved managementâs engagement of financial and legal advisors.
Bruker Cellular Analysis, Inc.
Equities
BLI
US0843101017
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |